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Montreal, Quebec, CanadaObjectives This study sought to compare the efﬁcacy of coronary artery bypass graft surgery (CABG) to that of
percutaneous coronary intervention (PCI) with ﬁrst-generation drug-eluting stents among patients with
multivessel disease (MVD), unprotected left main (LM) disease, and single-vessel proximal left anterior
descending (LAD) disease.
Background The efﬁcacy and safety of CABG versus PCI with drug-eluting stents in patient subgroups remains
controversial.
Methods We systematically searched Cardiosource, Circulation, Clinicaltrials.gov, the Cochrane Library, EMBASE,
and Medline for articles published through June 2013 for randomized controlled trials comparing CABG with PCI.
Primary endpoints included mortality, myocardial infarction, revascularization, and stroke. Data were meta-
analyzed with random-effects models.
Results We identiﬁed 7 randomized controlled trials (N ¼ 5,835): 2 of MVD (n ¼ 2,410, 100% diabetic), 2 of LM
disease (n ¼ 1,206, 29.0% diabetic), 1 of 3-vessel or LM disease (n ¼ 1,900, 25.5% diabetic), and 2 of single-vessel
proximal LAD disease (n ¼ 319, 36.3% diabetic). In MVD patients, CABG reduced the risk of mortality (risk ratio
[RR]: 0.70, 95% conﬁdence interval [CI]: 0.57 to 0.87), myocardial infarction (RR: 0.47, 95% CI: 0.36 to 0.61), and
repeat revascularization (RR: 0.36, 95% CI: 0.24 to 0.52), but increased stroke risk (RR: 1.72, 95% CI: 1.02 to 2.90). In
patients with LM disease, CABG reduced revascularization risk (RR: 0.60, 95% CI: 0.46 to 0.78) and increased
stroke risk (RR: 2.89, 95% CI: 1.15 to 7.27). Data for patients with single-vessel proximal LAD disease were
inconclusive.
Conclusions CABG is more efﬁcacious than is PCI with ﬁrst-generation drug-eluting stents in patients with LM
and MVD, at the cost of increased rates of stroke. No conclusion can be drawn for patients with single-vessel
proximal LAD disease. (J Am Coll Cardiol Intv 2014;7:497–506) ª 2014 by the American College of Cardiology
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498The efﬁcacy and safety of coronary artery bypass graft surgery
(CABG) versus percutaneous coronary intervention (PCI)
with ﬁrst-generation drug-eluting stents (DES) remains
controversial for the treatment of various patient subgroups.See page 507Although this topic has been researched in many observa-
tional studies (1–5), the recommended procedural choice
for patients within subgroups of vessel disease remains un-
clear due to a lack of data from randomized controlled
trials (RCTs). Therefore, our objective was to conduct a
meta-analysis of RCTs comparing the efﬁcacy and safety ofAbbreviations
and Acronyms
CABG = coronary artery
bypass graft surgery
CI = conﬁdence interval
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
HR = hazard ratio
LAD = left anterior
descending
LM = left main
MI = myocardial infarction
MIDCAB = minimally invasive
direct coronary artery bypass
graft surgery
MVD = multivessel disease
PES = paclitaxel-eluting
stent(s)
PCI = percutaneous coronary
intervention
RCT = randomized controlled
trial(s)
RR = risk ratio
SES = sirolimus-eluting
stent(s)CABG to that of PCI with ﬁrst-
generation DES among patients
with multivessel disease (MVD),
unprotected left main (LM) dis-
ease, and single-vessel proximal
left anterior descending artery
(LAD) disease.
Methods
Search strategy. We systemati-
cally searched the Cochrane
Library, EMBASE, andMedline
for articles published through
June 2013, with the terms “cor-
onary angiography” and “coro-
nary artery bypass surgery” and
“coronary artery bypass graft”
and “drug-eluting stents”. The
search was restricted to RCTs
conducted in humans and pub-
lished in English. In addition, we
searched Cardiosource, Circula-
tion, and Clinicaltrials.gov, and
we hand-searched the bibliogra-
phies of previous studies, relevant
reviews, and previous meta-
analyses to identify additionalstudies not found by our initial search. We conducted and
reported our meta-analysis according to guidelines described
in the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) (6) statement.
Study selection. We restricted inclusion to RCTs that
compared the efﬁcacy and safety of CABG to that of PCI
with ﬁrst-generation DES, as well as reported outcomes
of mortality, myocardial infarction (MI), revascularization,
or stroke. In addition, we only included trials in which the
majority of patients who underwent PCI received DES.
All studies not published in English were excluded.
Data extraction. Data extraction was performed by 2 re-
viewers, with disagreements resolved by consensus or bya third reviewer. Extracted data included study design,
enrollment period, duration of follow-up, vessel subtypes
(MVD, LM disease, proximal LAD disease), and the num-
ber of patients assigned to each group. Baseline participant
characteristics included age, sex, body mass index, type
2 diabetes mellitus, systemic hypertension, dyslipidemia,
previous MI, mean ejection fraction, and smoking. Extracted
outcomes of interest were all-cause mortality, MI, revascu-
larization, and stroke. Outcome data were extracted as
count data following an intention-to-treat approach at the
maximum available follow-up for all trials but FREEDOM
(Future Revascularization Evaluation in Patients With
Diabetes Mellitus: Optimal Management of Multivessel
Disease), where 5-year results were extracted.
Quality assessment. We used the Cochrane Collaboration
tool for assessing risk of bias to determine the quality of
included RCTs (7). This tool assesses the risk of selection
bias, performance bias, detection bias, attrition bias,
reporting bias, and other bias. Each RCT is categorized on
the basis of criteria determining the likelihood of potential
threats to validity. Quality assessment was independently
performed by 2 reviewers.
Data analysis. We used DerSimonian-Laird random-effects
meta-analysis models with inverse variance weighting to cal-
culate relative risks and corresponding 95% conﬁdence in-
tervals (CIs). In our primary analyses, we restricted inclusion
to trials in which all patients in the PCI group received DES.
In sensitivity analyses, we included RCTs in which the ma-
jority of patients received DES rather than bare-metal stents.
The amount of heterogeneity present was estimated using
the I2 statistic. To examine potential sources of heterogeneity,
we stratiﬁed our analyses by the following 3 types of coronary
disease: MVD, LM disease, and proximal LAD disease. We
visually inspected funnel plots and used the Egger test to assess
publication bias. All analyses were conducted using Stata
(version 11.2, Stata Corp., College Station, Texas).
Results
Search results. A total of 6,431 potentially relevant studies
were identiﬁed in our initial literature search (Fig. 1). After
screening the titles and abstracts of these studies, the full-
length texts of 68 potentially relevant publications were
retrieved and assessed for eligibility. Of these, 7 studies met
our inclusion criteria and were included in our meta-analysis.
No additional studies were identiﬁed through our manual
search of references of published studies, relevant reviews,
and previous meta-analyses.
Study characteristics. The earliest RCT we identiﬁed
comparing CABG with PCI with ﬁrst-generation DES was
published in 2005. Included studies had sample sizes ranging
from 130 to 1,900 patients and had follow-up durations
ranging from 6 to 60 months (Table 1). Three RCTs (8–10)
and a subgroup analysis (11) from the SYNTAX (Synergy
Figure 1. Flow Chart
Flow chart describing the systematic literature search for randomized controlled trials comparing coronary artery bypass graft surgery and percutaneous coronary
intervention with drug-eluting stents (DES).
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499Between Percutaneous Coronary Intervention With Taxus
and Cardiac Surgery) trial compared CABG with PCI with
DES in patients with MVD (n ¼ 4,210). Of note, the
MVD subgroup of the SYNTAX trial included only patients
with 3-vessel disease. Two RCTs (12,13) and another sub-
group (14) of patients from SYNTAX examined patients
with LM disease (n ¼ 801). Two RCTs (15,16) examined
patients with single-vessel proximal LAD disease (n ¼ 319).
All included RCTs had a low risk of bias according to the
Cochrane criteria (Online Appendix 1).
Procedure characteristics. Included RCTs varied with
respect to the chosen surgical revascularization technique
(Table 1). Both trials in patients with LM disease (12,13)
and 1 trial of patients with MVD (8) employed standard
CABG, whereas trials of patients with proximal LAD
disease (15,16) employed minimally invasive direct coro-
nary artery bypass graft surgery (MIDCAB). The 2
remaining trials (9,10) of patients with MVD selected the
surgical revascularization technique according to surgeons’
recommendations.
All stents employed in the included trials were ﬁrst-gen-
eration DES, including sirolimus-eluting stents (SES) and
paclitaxel-eluting stents (PES). Bare-metal stents were used
in a very small minority of patients with MVD (n ¼ 31).
Patient characteristics. Baseline patient characteristics were
well balanced across treatment groups. Most patients were
middle-aged men, one-quarter of whom were current
smokers (Online Appendix 2). Mean ejection fraction
ranged from 52.5% to 66.5%. Approximately two-thirds of
patients had hypertension, and two-thirds were hyper-
lipidemic. Among patients in both PCI and CABG groups,
about one-ﬁfth had experienced a previous MI.Trials of patients with MVD were predominantly (76.7%)
composed of patients with diabetes: 2 of the 3 largest RCTs
included in our meta-analysis, CARDia (Coronary Artery
Revascularization in Diabetes) (8) and FREEDOM (10),
both included an exclusively diabetic patient population
(Online Appendix 2). Slightly over one-quarter of patients
in the SYNTAX trial had diabetes. Diabetes was present in
29% of patients with LM disease and 36.3% of patients
with single-vessel proximal LAD disease.
Overall meta-analysis results. Overall, when data were
pooled across subgroups, CABG was superior relative to
PCI for mortality (Fig. 2) and MI (Fig. 3). However,
CABG, compared with PCI, resulted in increased rates of
stroke. Heterogeneity may be explained by vessel disease
subgroup, and these overall results were driven by the
strength of beneﬁcial effect of CABG in patients with MVD
(Table 2).
Meta-analysis of patient subgroups. Patients with MVD had
a signiﬁcantly reduced risk of all outcomes with CABG
compared with those for PCI with DES, with the exception
of stroke, which was increased (Fig. 4). Speciﬁcally, patients
with MVD who underwent CABG had a lower risk of
mortality (Fig. 2), MI (Fig. 3), and revascularization (Fig. 5).
There was no signiﬁcant difference between CABG and
PCI with DES in patients with LM disease for mortality
(Fig. 2) or MI (Fig. 3). However, patients with LM disease
had a lower risk of repeat revascularization (Fig. 5) and a
greater risk of stroke (Fig. 4) when undergoing CABG.
Treatment effect estimates for patients with single-vessel
LAD disease were accompanied by very wide CIs. Conse-
quently, no signiﬁcant difference was found between pro-
cedures for all outcomes.
Table 1. Characteristics of RCTs Comparing CABG to PCI with DES in Patients With MVD, LM Disease, and Proximal LAD Disease
Study, Year (Ref. #) Country
PCI
(n)
CABG
(n)
DES
(%)
PES
(%)
SES
(%)
BMS
(%) Type of Surgery
IMA
(%) Inclusion Exclusion
Follow-Up
(Months)
MVD
FREEDOM, 2012 (10) INT 953 947 100 43 51 0 Surgeons’ choice
(unspeciﬁed % MIDCAB)
0 DM, MVD, eligible for both
PCI and CABG
Severe CHF, previous cardiac
surgery, ACS
60
CARDia, 2010 (8) UK 256 254 69 0 69 31 Standard CABG 94 DM, MVD, complex SVD ACS, LM previous intervention 12
LM Disease
PRECOMBAT, 2011 (13) Korea 300 300 100 0 100 0 Standard CABG 0 LM ACS, previous intervention,
EF <30%
24
Boudriot, 2011 (12) Germany 100 101 100 2 98 0 Standard CABG 50 LM ACS, previous surgical
intervention, severe PVD
12
3-Vessel or LM Disease*
SYNTAX, 2009 (9) USA, Europe 903 897 100 100 0 0 Surgeons’ choice
(15% MIDCAB)
0 MVD and/or LM Previous intervention, acute MI 48
Proximal LAD Artery Disease
Hong, 2005 (16) Korea 119 70 100 20 80 0 MIDCAB 37 Isolated LAD stenosis ACS, previous intervention 6
Thiele, 2009 (15) Germany 65 65 100 0 100 0 MIDCAB 50 Isolated LAD stenosis ACS, previous intervention 36
*SYNTAX included patients with 3-vessel or LM disease. Secondary analyses were conducted in which patients were stratiﬁed by type of underlying coronary disease. Where possible, we present the results of these subgroup analyses in the current meta-analysis,
which were reported at the end of follow-up (48 months).
ACS ¼ acute coronary syndrome; BMS ¼ bare-metal stent; CABG ¼ coronary artery bypass graft surgery; CARDia ¼ Coronary Artery Revascularization in Diabetes; CHF ¼ congestive heart failure; DES ¼ drug-eluting stent; DM ¼ diabetes mellitus; EF ¼ ejection
fraction; FREEDOM ¼ Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease; IMA ¼ internal mammary artery; INT ¼ international; LAD ¼ left anterior descending; LM ¼ left main; MI ¼ myocardial
infarction; MIDCAB ¼ minimally invasive direct coronary artery bypass graft surgery; MVD ¼multivessel disease; PCI ¼ percutaneous coronary intervention; PES ¼ paclitaxel-eluting stent; PRECOMBAT ¼ Premier of Randomized Comparison of Bypass Surgery Versus
Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease; PVD¼ peripheral vascular disease; RCT¼ randomized controlled trial; SES ¼ sirolimus-eluting stent; SVD¼ single-vessel disease; SYNTAX ¼ Synergy Between Percutaneous
Coronary Intervention With Taxus and Cardiac Surgery.
A
l
A
li
et
al.
J
A
C
C
:
C
A
R
D
IO
V
A
S
C
U
L
A
R
IN
T
E
R
V
E
N
T
IO
N
S
,
V
O
L
.
7
,
N
O
.
5
,
2
0
1
4
C
A
B
G
Versus
P
C
I
W
ith
D
ES
M
A
Y
2
0
1
4
:4
9
7
–
5
0
6
5
0
0
Figure 2. Forest Plot of RCTs Comparing the Effect of CABG on All-Cause Mortality to That of PCI With DES
CABG ¼ coronary artery bypass graft surgery; CI ¼ conﬁdence interval; DES ¼ drug-eluting stents; FREEDOM ¼ Future Revascularization Evaluation in Patients With
Diabetes Mellitus: Optimal Management of Multivessel Disease; LAD ¼ left anterior descending; LM ¼ left main; MVD ¼ multivessel disease; PCI ¼ percutaneous
coronary intervention; PRECOMBAT ¼ Premier of Randomized Comparison of Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left
Main Coronary Artery Disease; RCT ¼ randomized controlled trial; RR ¼ risk ratio; SYNTAX ¼ Synergy Between Percutaneous Coronary Intervention With Taxus and
Cardiac Surgery.
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501Visual inspection of the funnel plot (Online Appendix 3)
and Egger test (p ¼ 0.025) suggested the presence of
publication bias.
Discussion
Our study was designed to compare the efﬁcacy and safety
of CABG with that of PCI with ﬁrst-generation DES
across subgroups of coronary artery vessel disease in terms
of mortality, MI, revascularization, and stroke. Our results
suggest that in patients with MVD, CABG reduces mor-
tality, MI, and repeat revascularization, but increases the
risk of stroke when compared with ﬁrst-generation DES.
In patients with LM disease, CABG was associated with
a reduced risk of revascularization, with an increased risk
of stroke, and no signiﬁcant differences in death or MI.
Available data were insufﬁcient to draw meaningful conclu-
sions regarding the relative efﬁcacies of CABG and PCI with
DES in patients with single-vessel proximal LAD disease.As an important caveat, both the FREEDOM and
CARDia trials were conducted in diabetic patients. Diabetes
is a well-known risk factor for cardiovascular disease, and
several studies have concluded that CABG is preferable
to PCI in diabetics (17,18). Two of the 3 largest RCTs
examining patients with MVD included an exclusively dia-
betic population; as a result, our ﬁndings showing a signif-
icant beneﬁt of CABG versus DES in MVD may be driven
by this effect. A recent study stratifying the results of the
SYNTAX trial by diabetes status found that diabetic pa-
tients with 3-vessel disease had a marked clinical beneﬁt
with CABG versus PCI with DES (18). This beneﬁt was
also present among nondiabetic patients, albeit less pro-
nounced. Among both diabetic and nondiabetic patients,
the rates of all-cause death were similar with both CABG
and PCI, whereas cardiac death occurred more frequently
with PCI than with CABG (nondiabetic hazard ratio [HR]:
1.62, 95% CI: 1.03 to 2.55; diabetic HR: 2.01, 95% CI:
1.04 to 3.88). Both diabetic and nondiabetic patients
Figure 3. Forest Plot of RCTs Comparing the Effect of CABG on MI to That of PCI With DES
Abbreviations as in Figure 2.
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502experienced higher rates of repeat revascularization after PCI
relative to CABG (diabetic HR: 2.75, 95% CI: 1.78 to 4.24,
p < 0.001; nondiabetic HR: 1.82, 95% CI: 1.39 to 2.38).
Nondiabetic patients had a higher rate of MI following
PCI relative to CABG (HR: 2.90, 95% CI: 1.70 to 4.70),
whereas no such difference was found among diabetic pa-
tients (HR: 1.62, 95% CI: 0.77 to 3.41). Neither diabetic
nor nondiabetic patients had signiﬁcantly different risks of
stroke across CABG or PCI. Together, these results suggest
that a protective effect conferred by CABG to patients withTable 2. Treatment Effects Obtained From the Meta-Analysis of RCTs Comparing
and Proximal LAD Disease*
Outcome Mortality
MVD 0.73 (0.56–0.96) 0.4
Unprotected LM disease 1.08 (0.75–1.57) 0.6
Single-vessel proximal LAD disease 2.34 (0.57–9.64) 1.8
Overall 0.85 (0.64–1.12) 0.5
Values are risk ratio (95% conﬁdence interval). *Data were pooled across trials using random-effects m
Abbreviations as in Table 1.3-vessel disease exists for both diabetic and nondiabetic
individuals.
CABG may also be beneﬁcial for patients with high
disease complexity and severity. The 3-vessel disease patient
subgroup in the SYNTAX trial also reported that patients
with more severe disease (as determined by the SYNTAX
score [19]) who received PCI had a signiﬁcantly higher risk
of mortality than did patients with high scores who received
CABG. Similarly, a recent meta-analysis of observational
and randomized studies found that, compared with patientsCABG to PCI With DES Overall and in Patients With MVD, LM Disease,
MI Revascularization Stroke
5 (0.34–0.60) 0.36 (0.26–0.51) 1.72 (1.02–2.90)
9 (0.41–1.16) 0.60 (0.46–0.78) 2.89 (1.15–7.27)
5 (0.46–7.40) 0.55 (0.05–6.24) 5.07 (0.21–122.80)
8 (0.40–0.84) 0.51 (0.39–0.67) 1.79 (1.23–2.62)
eta-analytic models.
Figure 4. Forest Plot of RCTs Comparing the Effect of CABG on Stroke to That of PCI With DES
Abbreviations as in Figure 2.
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503with low SYNTAX scores, those with high scores had
signiﬁcantly higher rates of major adverse cardiovascular
and cerebrovascular events with PCI than with CABG at
12, 24, and 36 months of follow-up (20). That is, the
beneﬁts of CABG versus PCI differ across disease severity.
Additional support is lent to this reasoning based on the
recent release of the 5-year follow-up data from the
SYNTAX trial: after 5 years, patients with severe disease
(as indicated by a high SYNTAX score) had lower mor-
tality rates among the CABG treatment group, relative to
the PCI group (21). Among patients with a low or inter-
mediate SYNTAX score, mortality rates were similar across
both treatment groups. However, patients with an inter-
mediate SYNTAX score had signiﬁcantly higher rates of
MI and repeat revascularization with PCI than with
CABG. Overall, the 5-year SYNTAX results show that
approximately two-thirds of patients with complex coro-
nary disease derive greater beneﬁt from CABG than from
PCI with ﬁrst-generation DES, whereas the remaining
patients may derive comparable beneﬁt from PCI. These
ﬁndings support the use of CABG in patients with MVD,
particularly among those with complex or severe disease.
Evidence for the optimal treatment of LM disease is less
clear. Results from our meta-analysis suggest a possiblebeneﬁt favoring CABG, albeit statistically inconclusive.
These inconclusive results may be due in part to the rela-
tively smaller sample size of patients with LM disease.
However, results from a large retrospective multinational
registry comparing CABG and PCI with ﬁrst-generation
DES in patients with LM disease also showed no difference
between procedures for death, MI, and cerebrovascular ac-
cidents at a median follow-up of 1,295 days (22). Our an-
alyses show that in patients with LM disease, CABG results
in a decreased risk of revascularization (Fig. 5) and an
increased risk of stroke (Fig. 4). Increasingly, however,
revascularization is not being considered as clinically sig-
niﬁcant as death, MI, or stroke (20,23). Thus, the evidence
favoring CABG over PCI with ﬁrst-generation DES for
patients with LM disease is not as strong as for patients
with MVD.
Our study had insufﬁcient power to draw clinically
directive conclusions for patients with single-vessel proximal
LAD disease. There are only 2 trials in patients with
proximal LAD disease, and these had a substantially shorter
duration of follow-up relative to all other included RCTs.
Although the evidence comparing CABG with PCI with
ﬁrst-generation DES is limited, a previous trial comparing
PCI with bare-metal stents found that patients undergoing
Figure 5. Forest Plot of RCTs Comparing the Effect of CABG on Repeat Revascularization to That of PCI With DES
Abbreviations as in Figure 2.
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504PCI had a higher risk of major adverse cardiovascular events
after 5 years (24). However, with the exception of a higher
risk of repeat revascularization with PCI, the risk of death
and MI was similar in both groups. Although these ﬁndings
suggest PCI may be comparable to CABG in patients with
proximal LAD disease, statistically inconclusive results
highlight the need to rely on additional clinical consider-
ations to aid in procedural choice.
Results from a recent study validating the SYNTAX
score II (25), an enhanced version of the SYNTAX score
with prognostically important clinical variables, conﬁrmed
the importance of considering clinical characteristics in
weighing the beneﬁts of CABG against those of PCI. The
investigators demonstrated that the low, intermediate, and
high anatomical complexity SYNTAX score categories
incorrectly categorized lower-risk patients in high SYNTAX
score groups and higher-risk patients in low SYNTAX score
groups. To correct for this misclassiﬁcation, the SYNTAX
score II considered additional patient factors including
age, creatinine clearance, left ventricular ejection fraction,
sex, chronic obstructive pulmonary disease, and peripheral
vascular disease. The presence of these clinical characteristicsmodiﬁed the threshold of the SYNTAX score at which
4-year mortality rates were similar between CABG and
PCI. Among patients with LM disease who underwent
PCI, higher anatomical SYNTAX scores were required to
achieve similar long-term prognosis as for patients who
received CABG. By contrast, among patients with 3-vessel
disease, the SYNTAX score was representative of greater
disease complexity than that for patients with LM disease
with identical SYNTAX scores. Thus, patients with 3-vessel
disease would have better long-term outcomes with CABG.
These ﬁndings highlight the importance of considering
all patient factors, particularly in the event where the choice
of procedure is not straightforward.
There is suggestive evidence that ﬁrst- and second-gen-
eration stents may have differential efﬁcacy proﬁles, which
in turn could affect the optimal procedural choice between
CABG and PCI with DES. Results from the SPIRIT IV
(Clinical Evaluation of the Xience V Everolimus Eluting
Coronary Stent System IV) trial (26) revealed that, at 1 year
after PCI, patients treated with everolimus-eluting stents
(EES), compared with patients treated with PES, had a
lower occurrence of MI (EES: 1.9%, PES: 3.1%, p ¼ 0.02),
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505deﬁnite stent thrombosis (EES: 0.3%, PES: 1.1%,
p ¼ 0.004), target lesion revascularization (EES: 2.5%,
PES: 4.6%, p ¼ 0.001), target vessel revascularization
(EES: 3.9%, PES: 5.9%, p ¼ 0.009), and major adverse
cardiovascular events (EES: 4.2%, PES: 6.9%, p < 0.001).
Similarly, 1-year post-PCI, results from the XAMI (Xience
V Stent vs. Cypher Stent in Primary PCI for Acute
Myocardial Infarction) trial (27) showed major adverse
cardiovascular event rates were signiﬁcantly lower among
patients treated with EES relative to SES (RR: 0.52, 95%
CI: 0.27- to 1.00, p ¼ 0.048). Although there may be
clinical differences attributable to stent type and generation,
it remains unclear to what extent these affect the choice
between second-generation DES and CABG.
Study limitations. First, the included RCTs varied in study
design, patient characteristics, procedural differences, and
duration of follow-up. To account for this between-study
heterogeneity, we used random-effects models. We also
stratiﬁed our analyses by type of coronary disease to explicitly
examine the impact of this source of heterogeneity. Second,
we found evidence of publication bias, which may have
resulted in an overestimate of the protective effects of
CABG. Although this may have affected our results for LM
or proximal LAD patients, it is unlikely to have biased our
MVD analyses as all trials in this patient subpopulation were
large (i.e., >500 patients) and thus likely to be published
regardless of statistical signiﬁcance. Third, diabetic patients
were over-represented in trials conducted in patients with
MVD. In addition, CABG and PCI with DES were only
compared in patients with single-vessel proximal LAD
disease in 2 relatively small RCTs to date; analyses con-
ducted in this subpopulation, therefore, had only modest
statistical power. Despite the varying duration of follow-up
across studies, the absence of reported event rates necessi-
tated the calculation of pooled relative risks. Among patients
with LAD disease, surgical outcomes referred solely to
MIDCAB, limiting our ability to comment on the efﬁcacy
of standard CABG for LAD disease. Finally, only ﬁrst-
generation DES were employed in all included RCTs,
limiting our ability to draw conclusions for second-genera-
tion devices.
Conclusions
We found that CABG has superior efﬁcacy when compared
to PCI with ﬁrst-generation DES in patients with MVD
but results in an increased risk of stroke. Among patients
with LM disease, CABG reduces the risk of revasculariza-
tion and increases the risk of stroke. Results were incon-
clusive in patients with single-vessel proximal LAD disease.
Our observed treatment beneﬁts in patients with MVD
but not others is consistent with the need to consider risk
proﬁles and disease complexity in selecting the optimal
revascularization procedure.Acknowledgment
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